Evaluation of the Effectiveness of Tenofovir in Chronic Hepatitis B Patients

Basit Öğe Kaydı
dc.contributor.authorErcin, Seval Müzeyyen
dc.contributor.authorÇalık Başaran, Nursel
dc.contributor.authorAladağ, Murat
dc.date.accessioned2021-03-24T08:07:13Z
dc.date.available2021-03-24T08:07:13Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAbstract: Objectives: HBV infection is a global public health problem. Tenofovir disoproxil fumarate and tenofovir alafenamide are nucleotide reverse transcriptase inhibitors and used for the treatment of chronic Hepatitis B infection. The aim of this study was to evaluate treatment response and efficacy of Tenofovir disoproxil fumarate. Materials and Methods: The study included hepatitis B positive patients who started to use Tenofovir disoproxil fumarate. We retrospectively reviewed electronic medical files of Hepatitis B patients. Hepatitis B surface antigen, Hepatitis B surface antibody, Hepatitis B e antigens, Hepatitis B e antibody, Hepatitis B viral DNA, aspartate aminotransferase, alanine aminotransferase values were evaluated in the 1st, 3rd, 6th, 9th, and 12th months. Result: None of the patients under Tenofovir disoproxil fumarate treatment was “primary resistant”. Alanine aminotransferase normalization at 12th month was seen in 80.4% of study population. Hepatitis B surface antigen seroconversion was detected only in one patient (0.85%) at 9th months and Hepatitis B e antigen seroconversion was observed in 9 patients (8.3%) under Tenofovir disoproxil fumarate treatment. At the sixth month of Tenofovir disoproxil fumarate treatment, complete response was found in 77 (65.8%), partial response in 21 (18%) and inadequate response were in 19 (16.2%). Among Hepatitis B e antigen positive patients, 44 (80 %) patients had undetectable Hepatitis B virus DNA levels at the end of 12th month and among Hepatitis B e antigens negative patients, 52 (91.2%) patients had undetectable Hepatitis B DNA levels at the end of 12th month (p<0.01). Conclusion: Among patients with chronic HBV infection, Tenofovir disoproxil fumarate had satisfying antiviral efficacy. There is no primary resistance in patients treated with Tenofovir disoproxil fumarate. Patients had statistically significant improvement in aspartate aminotransferase, alanine aminotransferase, Hepatit B virus DNA levels.en_US
dc.identifier.citationERCİN S. M,BAŞARAN N. Ç,ALADAĞ M (2020). Evaluation of the Effectiveness of Tenofovir in Chronicm Hepatitis B Patients. Acta Medica, 51(1), 9 - 14. Doi: 10.32552/0.ActaMedica.423en_US
dc.identifier.doi10.32552/0.ActaMedica.423en_US
dc.identifier.endpage14en_US
dc.identifier.issn2147-9488
dc.identifier.issue1en_US
dc.identifier.startpage9en_US
dc.identifier.trdizinid378776en_US
dc.identifier.urihttps://doi.org/10.32552/0.ActaMedica.423
dc.identifier.urihttps://hdl.handle.net/11616/19713
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/378776
dc.identifier.volume51en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofActa Medicaen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleEvaluation of the Effectiveness of Tenofovir in Chronic Hepatitis B Patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Makale Dosyası.pdf
Boyut:
119.22 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Doyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu